Medications for Opioid Use Disorder in Pregnancy | Part 2
Opioid use disorder (OUD) in the US continues to rise, including among women of childbearing age. Pregnant women with opioid use disorder face many barriers to care, including stigma, limited access to treatment, and fear of legal consequences. The speaker will cover the science and best practices in treating pregnant women with OUD and their infants, as well as a panel focused on case review and discussion.
Learning Objectives
Following participation in this course, participants should be able to:
- Explain how stigma affects women's ability to access treatment for Opioid Use Disorder
(OUD) while pregnant - Define the Standard of Care for treatment of pregnant women with OUD
- Understand the three medication options available for OUD and the evidence for each
treatment in pregnancy - Develop guidelines for initiating and continuing buprenorphine treatment during pregnancy
- Identify high risk periods for overdose/death related to OUD
- Discuss the role of drug testing while treating pregnant women in their own setting
- Understand the role of Medications for Opioid Use Disorder (MOUD) in women with polysubstance use
- Discuss legal/liability concerns related to treating pregnant women with SUD and take steps to minimize this risk
- Recognize common signs/symptoms of Neonatal Opioid Withdrawal Syndrome (NOWS)
- Describe the differences between traditional NAS/NOWS treatment and Eat, Sleep,
Console Methodology
Additional Information
Candy Stockton, MD, FASAM
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nevada, Reno School of Medicine and the Division of Child and Family Services. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education to physicians.
Physicians: The University of Nevada, Reno School of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: The University of Nevada, Reno School of Medicine approves this program for 1.25 hours of nursing continuing education credit.
AB474: This program provides 1.25 CME credit towards the Nevada State Board of Medical Examiners' requirement for 2 hours of training related to the misuse and abuse of controlled substances, the prescribing of opioids, or addiction during each licensure period.
Available Credit
- 1.25 AMA PRA Category 1 Credit™
Price
This course is offered through University of Nevada, Reno School of Medicine.
To take this course you will be redirected to University of Nevada, Reno School of Medicine's website. You must login or create an account with University of Nevada, Reno School of Medicine in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!